Soluble Vascular Cell Adhesion Molecule-1 (sVCAM-1) and Natalizumab Serum Concentration as Potential Biomarkers for Pharmacodynamics and Treatment Response of Patients with Multiple Sclerosis Receiving Natalizumab.
Journal
CNS drugs
ISSN: 1179-1934
Titre abrégé: CNS Drugs
Pays: New Zealand
ID NLM: 9431220
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
accepted:
31
08
2022
pubmed:
30
9
2022
medline:
13
10
2022
entrez:
29
9
2022
Statut:
ppublish
Résumé
Natalizumab (NTZ) is an established treatment for highly active, relapsing-remitting multiple sclerosis. In the context of rare progressive multifocal leukoencephalopathy and extended interval dosing as a treatment option, biomarkers for treatment monitoring are required. Natalizumab serum concentration (NTZ SC) and soluble vascular cell adhesion molecule 1 (sVCAM-1) concentration were shown to change on treatment with NTZ. We aimed to investigate whether NTZ SC and sVCAM-1 could be suitable pharmacodynamic markers and whether they could predict disease activity on NTZ, improving the concept of personalized multiple sclerosis treatment. In a retrospective study at the Medical University of Innsbruck, Austria, we identified patients treated with NTZ and chose samples longitudinally collected during routine follow-ups for the measurement of NTZ SC and sVCAM-1 by an enzyme-linked immunosorbent assay. We correlated these with clinical and demographic variables and clinical outcomes. Furthermore, we analyzed the stability of NTZ SC and sVCAM-1 during treatment. One hundred and thirty-seven patients were included. We found a strong negative correlation between NTZ SC and sVCAM-1. Both showed significant associations with body mass index, infusion interval, sample age, and anti-drug-antibodies. Natalizumab serum concentration was reduced in extended interval dosing, but not sVCAM-1. Only sVCAM-1 showed a weak association with relapses during treatment, while there was no association with disease progression. Both NTZ SC and sVCAM-1 showed a wide inter-individual distribution while levels in single patients were stable on treatment. Soluble vascular cell adhesion molecule 1 is a suitable pharmacodynamic marker during treatment with NTZ, which is significantly reduced already after the first dose, remains stable in individual patients even on extended interval dosing, and strongly correlates with NTZ SC. Because of the high inter-individual range, absolute levels of sVCAM-1 and NTZ SC are difficult to introduce as treatment monitoring biomarkers in order to predict disease activity in single patients.
Sections du résumé
BACKGROUND
Natalizumab (NTZ) is an established treatment for highly active, relapsing-remitting multiple sclerosis. In the context of rare progressive multifocal leukoencephalopathy and extended interval dosing as a treatment option, biomarkers for treatment monitoring are required. Natalizumab serum concentration (NTZ SC) and soluble vascular cell adhesion molecule 1 (sVCAM-1) concentration were shown to change on treatment with NTZ. We aimed to investigate whether NTZ SC and sVCAM-1 could be suitable pharmacodynamic markers and whether they could predict disease activity on NTZ, improving the concept of personalized multiple sclerosis treatment.
METHODS
In a retrospective study at the Medical University of Innsbruck, Austria, we identified patients treated with NTZ and chose samples longitudinally collected during routine follow-ups for the measurement of NTZ SC and sVCAM-1 by an enzyme-linked immunosorbent assay. We correlated these with clinical and demographic variables and clinical outcomes. Furthermore, we analyzed the stability of NTZ SC and sVCAM-1 during treatment.
RESULTS
One hundred and thirty-seven patients were included. We found a strong negative correlation between NTZ SC and sVCAM-1. Both showed significant associations with body mass index, infusion interval, sample age, and anti-drug-antibodies. Natalizumab serum concentration was reduced in extended interval dosing, but not sVCAM-1. Only sVCAM-1 showed a weak association with relapses during treatment, while there was no association with disease progression. Both NTZ SC and sVCAM-1 showed a wide inter-individual distribution while levels in single patients were stable on treatment.
CONCLUSIONS
Soluble vascular cell adhesion molecule 1 is a suitable pharmacodynamic marker during treatment with NTZ, which is significantly reduced already after the first dose, remains stable in individual patients even on extended interval dosing, and strongly correlates with NTZ SC. Because of the high inter-individual range, absolute levels of sVCAM-1 and NTZ SC are difficult to introduce as treatment monitoring biomarkers in order to predict disease activity in single patients.
Identifiants
pubmed: 36173556
doi: 10.1007/s40263-022-00953-x
pii: 10.1007/s40263-022-00953-x
doi:
Substances chimiques
Biomarkers
0
Natalizumab
0
Nitro Compounds
0
Thiazoles
0
Vascular Cell Adhesion Molecule-1
0
nitazoxanide
SOA12P041N
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1121-1131Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Rudick RA, Polman CH, Clifford D, Miller D, Steinman L. Natalizumab: bench to bedside and beyond. JAMA Neurol. 2013;70:172–82. https://doi.org/10.1001/jamaneurol.2013.598 .
doi: 10.1001/jamaneurol.2013.598
pubmed: 23128399
Polman CH, O’Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, AFFIRM Investigators, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354:899–910. https://doi.org/10.1056/NEJMoa044397 .
doi: 10.1056/NEJMoa044397
pubmed: 16510744
Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, SENTINEL Investigators, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354:911–23. https://doi.org/10.1056/NEJMoa044396 .
doi: 10.1056/NEJMoa044396
pubmed: 16510745
Calabresi PA, Prat A, Biernacki K, Rollins J, Antel JP. T lymphocytes conditioned with Interferon beta induce membrane and soluble VCAM on human brain endothelial cells. J Neuroimmunol. 2001;115:161–7. https://doi.org/10.1016/s0165-5728(01)00253-3 .
doi: 10.1016/s0165-5728(01)00253-3
pubmed: 11282166
Garton KJ, Gough PJ, Philalay J, Wille PT, Blobel CP, Whitehead RH, et al. Stimulated shedding of vascular cell adhesion molecule 1 (VCAM-1) is mediated by tumor necrosis factor-alpha-converting enzyme (ADAM 17). J Biol Chem. 2003;278:37459–64. https://doi.org/10.1074/jbc.M305877200 .
doi: 10.1074/jbc.M305877200
pubmed: 12878595
Singh RJR, Mason JC, Lidington EA, Edwards DR, Nuttall RK, Khokha R, et al. Cytokine stimulated vascular cell adhesion molecule-1 (VCAM-1) ectodomain release is regulated by TIMP-3. Cardiovasc Res. 2005;67:39–49. https://doi.org/10.1016/j.cardiores.2005.02.020 .
doi: 10.1016/j.cardiores.2005.02.020
pubmed: 15949468
Millonig A, Hegen H, Di Pauli F, Ehling R, Gneiss C, Hoelzl M, et al. Natalizumab treatment reduces endothelial activity in MS patients. J Neuroimmunol. 2010;227:190–4. https://doi.org/10.1016/j.jneuroim.2010.07.012 .
doi: 10.1016/j.jneuroim.2010.07.012
pubmed: 20739072
Oppermann K, Pilz G, Wipfler P, Sulzer C, Afazel S, Haschke-Becher E, et al. Effect of natalizumab treatment on soluble adhesion molecules. Aktuelle Neurol. 2009;36:P675. https://doi.org/10.1055/s-0029-1238768 .
doi: 10.1055/s-0029-1238768
Haarmann A, Nowak E, Deiß A, van der Pol S, Monoranu CM, Kooij G, et al. Soluble VCAM-1 impairs human brain endothelial barrier integrity via integrin α-4-transduced outside-in signaling. Acta Neuropathol. 2015;129:639–52. https://doi.org/10.1007/s00401-015-1417-0 .
doi: 10.1007/s00401-015-1417-0
pubmed: 25814153
pmcid: 4405352
Hartung HP, Reiners K, Archelos JJ, Michels M, Seeldrayers P, Heidenreich F, et al. Circulating adhesion molecules and tumor necrosis factor receptor in multiple sclerosis: correlation with magnetic resonance imaging. Ann Neurol. 1995;38:186–93. https://doi.org/10.1002/ana.410380210 .
doi: 10.1002/ana.410380210
pubmed: 7544573
Ryerson LZ, Foley J, Chang I, Kister I, Cutter G, Metzger RR, et al. Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing. Neurology. 2019;93:e1452–62. https://doi.org/10.1212/WNL.0000000000008243 .
doi: 10.1212/WNL.0000000000008243
pubmed: 31515290
pmcid: 7010325
Foley JF, Goelz S, Hoyt T, Christensen A, Metzger RR. Evaluation of natalizumab pharmacokinetics and pharmacodynamics with standard and extended interval dosing. Mult Scler Relat Disord. 2019;31:65–71. https://doi.org/10.1016/j.msard.2019.03.017 .
doi: 10.1016/j.msard.2019.03.017
pubmed: 30939392
Ryerson LZ, Li X, Goldberg JD, Hoyt T, Christensen A, Metzger RR, et al. Pharmacodynamics of natalizumab extended interval dosing in MS. Neurol Neuroimmunol Neuroinflamm. 2020;7: e672. https://doi.org/10.1212/NXI.0000000000000672 .
doi: 10.1212/NXI.0000000000000672
Van Kempen ZLE, Leurs CE, Witte BI, de Vries A, Wattjes MP, Rispens T, et al. The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing. Mult Scler. 2018;24:805–10. https://doi.org/10.1177/1352458517708464 .
doi: 10.1177/1352458517708464
pubmed: 28485678
Bsteh G, Ehling R, Lutterotti A, Hegen H, Di Pauli F, Auer M, et al. Long term clinical prognostic factors in relapsing-remitting multiple sclerosis: insights from a 10-year observational study. PLoS One. 2016;11: e0158978. https://doi.org/10.1371/journal.pone.0158978 .
doi: 10.1371/journal.pone.0158978
pubmed: 27391947
pmcid: 4938610
Deisenhammer F, Jank M, Lauren A, Sjödin A, Ryner M, Fogdell-Hahn A, ABIRISK consortium, et al. Prediction of natalizumab anti-drug antibodies persistency. Mult Scler. 2019;25:392–8. https://doi.org/10.1177/1352458517753721 .
doi: 10.1177/1352458517753721
pubmed: 29336205
Tabachnick BG, Fidell LS, Ullman JB. Using multivariate statistics. 5th ed. Boston: Pearson; 2007.
Lorscheider J, Buzzard K, Jokubaitis V, Spelman T, Havrdova E, Horakova D, et al. on behalf of the MSBase Study Group. Defining secondary progressive multiple sclerosis. Brain. 2016;139:2395–405. https://doi.org/10.1093/brain/aww173 .
doi: 10.1093/brain/aww173
pubmed: 27401521
Council National Research. The prevention and treatment of missing data in clinical trials. Washington, DC: National Academies Press (US); 2010.
Fritz CO, Morris PE, Richler JJ. Effect size estimates: current use, calculations, and interpretation. J Exp Psychol Gen. 2012;141:2–18. https://doi.org/10.1037/a0024338 .
doi: 10.1037/a0024338
pubmed: 21823805
Pugliatti M, Rosati G, Carton H, Riise T, Drulovic J, Vécsei L, et al. The epidemiology of multiple sclerosis in Europe. Eur J Neurol. 2006;13:700–22. https://doi.org/10.1111/j.1468-1331.2006.01342.x .
doi: 10.1111/j.1468-1331.2006.01342.x
pubmed: 16834700
Rieckmann P, Kruse N, Nagelkerken L, Beckmann K, Miller D, Polman C, et al. Soluble vascular cell adhesion molecule (VCAM) is associated with treatment effects of interferon beta-1b in patients with secondary progressive multiple sclerosis. J Neurol. 2005;252:526–33. https://doi.org/10.1007/s00415-005-0681-7 .
doi: 10.1007/s00415-005-0681-7
pubmed: 15895275
Mancuso R, Agostini S, Hernis A, Caputo D, Galimberti D, Scarpini E, et al. Alterations of the miR-126-3p/POU2AF1/Spi-B axis and JCPyV reactivation in multiple sclerosis patients receiving natalizumab. Front Neurol. 2022;13: 819911. https://doi.org/10.3389/fneur.2022.819911 .
doi: 10.3389/fneur.2022.819911
pubmed: 35359635
pmcid: 8963350
Jasiak-Zatońska M, Pietrzak A, Wyciszkiewicz A, Więsik-Szewczyk E, Pawlak-Buś K, Leszczyński P, et al. Different blood-brain-barrier disruption profiles in multiple sclerosis, neuromyelitis optica spectrum disorders, and neuropsychiatric systemic lupus erythematosus. Neurol Neurochir Pol. 2022;56:246–55. https://doi.org/10.5603/PJNNS.a2022.0013 .
doi: 10.5603/PJNNS.a2022.0013
pubmed: 35118639
Calabresi PA, Giovannoni G, Confavreux C, Galetta SL, Havrdova E, Hutchinson M, AFFIRM and SENTINEL Investigators, et al. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology. 2007;69:1391–403. https://doi.org/10.1212/01.wnl.0000277457.17420.b5 .
doi: 10.1212/01.wnl.0000277457.17420.b5
pubmed: 17761550
Van Kempen ZLE, Hoogervorst ELJ, Wattjes MP, Kalkers NF, Mostert JP, Lissenberg-Witte BI, et al. Personalized extended interval dosing of natalizumab in MS: a prospective multicenter trial. Neurology. 2020;95:e745–54. https://doi.org/10.1212/WNL.0000000000009995 .
doi: 10.1212/WNL.0000000000009995
pubmed: 32690785
Serra López-Matencio JM, Pérez García Y, Meca-Lallana V, Juárez-Sánchez R, Ursa A, Vega-Piris L, et al. Evaluation of natalizumab pharmacokinetics and pharmacodynamics: toward individualized doses. Front Neurol. 2021;12: 716548. https://doi.org/10.3389/fneur.2021.716548 .
doi: 10.3389/fneur.2021.716548
pubmed: 34690914
pmcid: 8529019
Van Kempen ZLE, Leurs CE, Vennegoor A, Wattjes MP, Rispens T, Uitdehaag BM, et al. Natalizumab-associated progressive multifocal leukoencephalopathy is not preceded by elevated drug concentrations. Mult Scler. 2017;23:995–9. https://doi.org/10.1177/1352458516684023 .
doi: 10.1177/1352458516684023
pubmed: 28112019
Tanaka M, Kinoshita M, Foley JF, Tanaka K, Kira J, Carroll WM. Body weight-based natalizumab treatment in adult patients with multiple sclerosis. J Neurol. 2015;262:781–2. https://doi.org/10.1007/s00415-015-7655-1 .
doi: 10.1007/s00415-015-7655-1
pubmed: 25663410
Vennegoor A, Rispens T, Strijbis EM, Seewann A, Uitdehaag BM, Balk LJ, et al. Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis. Mult Scler. 2013;19:593–600. https://doi.org/10.1177/1352458512460604 .
doi: 10.1177/1352458512460604
pubmed: 22992450
Plavina T, Muralidharan KK, Kuesters G, Mikol D, Evans K, Subramanyam M, et al. Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients. Neurology. 2017;89:1584–93. https://doi.org/10.1212/WNL.0000000000004485 .
doi: 10.1212/WNL.0000000000004485
pubmed: 28916537
pmcid: 5634662
Kraus J, Engelhardt B, Chatzimanolis N, Bauer R, Tofighi J, Kuehne BS, et al. Cell surface bound and soluble adhesion molecules in CSF and blood in multiple sclerosis: correlation with MRI-measures of subclinical disease severity and activity. J Neuroimmunol. 2002;122:175–85. https://doi.org/10.1016/s0165-5728(01)00469-6 .
doi: 10.1016/s0165-5728(01)00469-6
pubmed: 11777557
Khoy K, Mariotte D, Defer G, Petit G, Toutirais O, Le Mauff B. Natalizumab in multiple sclerosis treatment: from biological effects to immune monitoring. Front Immunol. 2020;11: 549842. https://doi.org/10.3389/fimmu.2020.549842 .
doi: 10.3389/fimmu.2020.549842
pubmed: 33072089
pmcid: 7541830
Petersen ER, Søndergaard HB, Oturai AB, Jensen P, Sorensen PS, Sellebjerg F, et al. Soluble serum VCAM-1, whole blood mRNA expression and treatment response in natalizumab-treated multiple sclerosis. Mult Scler Relat Disord. 2016;10:66–72. https://doi.org/10.1016/j.msard.2016.09.001 .
doi: 10.1016/j.msard.2016.09.001
pubmed: 27919501
Granell-Geli J, Izquierdo-Gracia C, Sellés-Rius A, Teniente-Serra A, Presas-Rodríguez S, Mansilla MJ, et al. Assessing blood-based biomarkers to define a therapeutic window for natalizumab. J Pers Med. 2021;11:1347. https://doi.org/10.3390/jpm11121347 .
doi: 10.3390/jpm11121347
pubmed: 34945819
pmcid: 8706232
Defer G, Mariotte D, Derache N, Toutirais O, Legros H, Cauquelin B, et al. CD49d expression as a promising biomarker to monitor natalizumab efficacy. J Neurol Sci. 2012;15(314):138–42. https://doi.org/10.1016/j.jns.2011.10.005 .
doi: 10.1016/j.jns.2011.10.005
Khademi M, Bornsen L, Rafatnia F, Andersson M, Brundin L, Piehl F, et al. The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers. Eur J Neurol. 2009;16:528–36. https://doi.org/10.1111/j.1468-1331.2009.02532.x .
doi: 10.1111/j.1468-1331.2009.02532.x
pubmed: 19220425